Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. In 2016, 1,685,210 new cancer cases and 595,690 cancer deaths are projected to occur in the United States. Overall cancer incidence trends (13 oldest SEER registries) are stable in women, but declining by 3.1% per year in men (from 2009-2012), much of which is because of recent rapid declines in prostate cancer diagnoses. The cancer death rate has dropped by 23% since 1991, translating to more than 1.7 million deaths averted through 2012. Despite this progress, death rates are increasing for cancers of the liver, pancreas, and uterine corpus, and cancer is now the leading cause of death in 21 states, primarily due to exceptionally large reductions in death from heart disease. Among children and adolescents (aged birth-19 years), brain cancer has surpassed leukemia as the leading cause of cancer death because of the dramatic therapeutic advances against leukemia. Accelerating progress against cancer requires both increased national investment in cancer research and the application of existing cancer control knowledge across all segments of the population.

/pdf/cancer-statistics-2016-3jk3ht2xd2.pdf

Cancer statistics, 2016

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. In 2017, 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the United States. For all sites combined, the cancer incidence rate is 20% higher in men than in women, while the cancer death rate is 40% higher. However, sex disparities vary by cancer type. For example, thyroid cancer incidence rates are 3-fold higher in women than in men (21 vs 7 per 100,000 population), despite equivalent death rates (0.5 per 100,000 population), largely reflecting sex differences in the "epidemic of diagnosis." Over the past decade of available data, the overall cancer incidence rate (2004-2013) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2005-2014) declined by about 1.5% annually in both men and women. From 1991 to 2014, the overall cancer death rate dropped 25%, translating to approximately 2,143,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the cancer death rate was 15% higher in blacks than in whites in 2014, increasing access to care as a result of the Patient Protection and Affordable Care Act may expedite the narrowing racial gap; from 2010 to 2015, the proportion of blacks who were uninsured halved, from 21% to 11%, as it did for Hispanics (31% to 16%). Gains in coverage for traditionally underserved Americans will facilitate the broader application of existing cancer control knowledge across every segment of the population. CA Cancer J Clin 2017;67:7-30. © 2017 American Cancer Society.

https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21387

Cancer statistics, 2017

Each year the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. A total of 1,658,370 new cancer cases and 589,430 cancer deaths are projected to occur in the United States in 2015. During the most recent 5 years for which there are data (2007-2011), delay-adjusted cancer incidence rates (13 oldest SEER registries) declined by 1.8% per year in men and were stable in women, while cancer death rates nationwide decreased by 1.8% per year in men and by 1.4% per year in women. The overall cancer death rate decreased from 215.1 (per 100,000 population) in 1991 to 168.7 in 2011, a total relative decline of 22%. However, the magnitude of the decline varied by state, and was generally lowest in the South (∼15%) and highest in the Northeast (≥20%). For example, there were declines of 25% to 30% in Maryland, New Jersey, Massachusetts, New York, and Delaware, which collectively averted 29,000 cancer deaths in 2011 as a result of this progress. Further gains can be accelerated by applying existing cancer control knowledge across all segments of the population.

/pdf/cancer-statistics-2015-42anew2xb1.pdf

Cancer statistics, 2015.

WRITING GROUP MEMBERS Emelia J. Benjamin, MD, SCM, FAHA Michael J. Blaha, MD, MPH Stephanie E. Chiuve, ScD Mary Cushman, MD, MSc, FAHA Sandeep R. Das, MD, MPH, FAHA Rajat Deo, MD, MTR Sarah D. de Ferranti, MD, MPH James Floyd, MD, MS Myriam Fornage, PhD, FAHA Cathleen Gillespie, MS Carmen R. Isasi, MD, PhD, FAHA Monik C. Jiménez, ScD, SM Lori Chaffin Jordan, MD, PhD Suzanne E. Judd, PhD Daniel Lackland, DrPH, FAHA Judith H. Lichtman, PhD, MPH, FAHA Lynda Lisabeth, PhD, MPH, FAHA Simin Liu, MD, ScD, FAHA Chris T. Longenecker, MD Rachel H. Mackey, PhD, MPH, FAHA Kunihiro Matsushita, MD, PhD, FAHA Dariush Mozaffarian, MD, DrPH, FAHA Michael E. Mussolino, PhD, FAHA Khurram Nasir, MD, MPH, FAHA Robert W. Neumar, MD, PhD, FAHA Latha Palaniappan, MD, MS, FAHA Dilip K. Pandey, MBBS, MS, PhD, FAHA Ravi R. Thiagarajan, MD, MPH Mathew J. Reeves, PhD Matthew Ritchey, PT, DPT, OCS, MPH Carlos J. Rodriguez, MD, MPH, FAHA Gregory A. Roth, MD, MPH Wayne D. Rosamond, PhD, FAHA Comilla Sasson, MD, PhD, FAHA Amytis Towfighi, MD Connie W. Tsao, MD, MPH Melanie B. Turner, MPH Salim S. Virani, MD, PhD, FAHA Jenifer H. Voeks, PhD Joshua Z. Willey, MD, MS John T. Wilkins, MD Jason HY. Wu, MSc, PhD, FAHA Heather M. Alger, PhD Sally S. Wong, PhD, RD, CDN, FAHA Paul Muntner, PhD, MHSc On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart Disease and Stroke Statistics—2017 Update

Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association

The 11th edition of Harrison's Principles of Internal Medicine welcomes Anthony Fauci to its editorial staff, in addition to more than 85 new contributors. While the organization of the book is similar to previous editions, major emphasis has been placed on disorders that affect multiple organ systems. Important advances in genetics, immunology, and oncology are emphasized. Many chapters of the book have been rewritten and describe major advances in internal medicine. Subjects that received only a paragraph or two of attention in previous editions are now covered in entire chapters. Among the chapters that have been extensively revised are the chapters on infections in the compromised host, on skin rashes in infections, on many of the viral infections, including cytomegalovirus and Epstein-Barr virus, on sexually transmitted diseases, on diabetes mellitus, on disorders of bone and mineral metabolism, and on lymphadenopathy and splenomegaly. The major revisions in these chapters and many

Harrison's Principles of Internal Medicine

This report builds on a highly valued predecessor, the 1994 Institute of Medicine (IOM) report entitled Reducing Risks for Mental Disorders: Frontiers for Preventive Intervention Research. That report provided the basis for understanding prevention science, elucidating its then-existing research base, and contemplating where it should go in the future. This report documents that an increasing number of mental, emotional, and behavioral problems in young people are in fact preventable. The proverbial ounce of prevention will indeed be worth a pound of cure: effectively applying the evidence-based prevention interventions at hand could potentially save billions of dollars in associated costs by avoiding or tempering these disorders in many individuals. Furthermore, devoting significantly greater resources to research on even more effective prevention and promotion efforts, and then reliably implementing the findings of such research, could substantially diminish the human and economic toll.

Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities

1. Tobacco Warfare In America: An Overview.- A Battlefield Tour.- American Principles, Public Policy, and Tobacco Warfare.- Organization of this Book.- 2. Welfare Economics, Public Policy, And Smoking.- Smoking, the Market Process, and a Free Society.- Taxation and Regulation in a Market Economy.- Welfare Economics and Tobacco Policy.- Tobacco Taxation as Corrective Taxation.- Tobacco Taxation: An Overview.- 3. The Taxation And Regulation of Smoking: Principle vs. Expediency.- Realistic Politics and Tobacco Policy.- Knowledge and the Improbability of Corrective Taxation.- Political Incentive and Actual Tobacco Taxation.- Rationale, Reality, and Tobacco Regulation.- Tobacco Policy in Constitutional Perspective.- 4. Smoking And The Economic Cost Of Lost Production.- Smoking and Health: The Method of "Attributable Risk".- How Accurate are Measures of Attributable Risk?.- Economic Measurement of Indirect Costs.- Joint Costs and Improper Cost Attribution.- Who Loses Lost Production: Smokers or Nonsmokers?.- What about the Benefits of Smoking?.- 5. Markets, Insurance, And The Medical Costs Of Smokers.- Attribution of "Medical Costs" to Smoking.- Medical Costs, Personal Responsibility, and Insurance.- Life Insurance and Nonsmoker Discounts.- Health Insurance and Smoker-Nonsmoker Parity.- Smoking and Fire Costs.- Moral Hazard and Insurance Costs.- 6. Medicare, Medicaid, And The Social Cost Of Smoking.- Smokers and the Cost of Medicare.- Transfers and Social Costs: A Clarification.- Proposals for Earmarked Cigarette Taxes.- Principle, Expediency, and Wealth Transfers.- 7. Smoking, Business Costs, And Social Cost.- Smoking and the Efficiency of Team Production.- Smoking and Workplace Efficiency.- Workplace Costs: A Further Consideration.- Smoking and Economic Productivity: A Conceptual Framework.- Smoking and Productivity: Discussion of the Data.- 8. ETS And Governmental Protection Of Consumers And Workers.- The Economics of Clean Indoor Air Acts.- The Coase Theorem, Ownership Rights, and Markets.- An Alternative Explanation.- Tobacco and "Public Health".- 9. Advertising, "Addiction," And The Denial Of True Choice.- Separating Advertising Myth from Advertising Reality.- Impact of Cigarette Advertising on Smoking by Youth.- Cigarette Advertising is a Firm-Specific Investment.- International Evidence: Cigarette Advertising Bans do not Work.- The Constitution and the Protection of Commercial Speech.- Advertising and Addiction.- The New Economics of Addiction.- Consumer Sovereignty or Health Fascism?.- 10. Self Interest, Public Interest, And Legislation.- Corrective Cigarette Taxation: An Analytical Unicorn.- An Economic Approach to Legislation and Regulation.- Democratic Politics and Tax Policy.- Rent Seeking, Tax Resistance, and Social Waste.- The Social Cost of Tobacco Taxation: A Recalculation.- Economic Principles and the Anti-Cancer Bureaucracy.- Tobacco Taxation and Regulation: A Realistic Approach.- 11. Interest Groups And The Public's Health.- Overview.- Market Processes and Personal Health.- Is Health Research a Public Good?.- Public Health and the Collective Interests of Physicians.- Self Interest in Public Interest Organizations.- 12. Principle And Expediency In Public Policy.- Principles of Constitutional Political Economy.- The Self-Ownership Foundations of a Democratic Polity.- Considerations from the Economic Theory of Legislation.- Implications for Public Policy Toward Tobacco.- Implications for Public Policy More Broadly Considered.- References.

/pdf/the-economics-of-smoking-1hd662nqi1.pdf

The economics of smoking

Context: In 1954 the tobacco industry paid to publish the “Frank Statement to Cigarette Smokers” in hundreds of U.S. newspapers. It stated that the public’s health was the industry’s concern above all others and promised a variety of good-faith changes. What followed were decades of deceit and actions that cost millions of lives. In the hope that the food history will be written differently, this article both highlights important lessons that can be learned from the tobacco experience and recommends actions for the food industry. Methods: A review and analysis of empirical and historical evidence pertaining to tobacco and food industry practices, messages, and strategies to influence publicopinion,legislationandregulation,litigation,andtheconductofscience. Findings: The tobacco industry had a playbook, a script, that emphasized personal responsibility, paying scientists who delivered research that instilled doubt,criticizingthe“junk”sciencethatfoundharmsassociatedwithsmoking, making self-regulatory pledges, lobbying with massive resources to stifle governmentaction,introducing“safer”products,andsimultaneouslymanipulating and denying both the addictive nature of their products and their marketing to children. The script of the food industry is both similar to and different from the tobacco industry script. Conclusions: Food is obviously different from tobacco, and the food industry differs from tobacco companies in important ways, but there also are significant similaritiesintheactionsthattheseindustrieshavetakeninresponsetoconcern that their products cause harm. Because obesity is now a major global problem,

http://foodaddictionsummit.org/documents/BrownellWarnerFoodTobaccoMilbank09.pdf

The perils of ignoring history: Big Tobacco played dirty and millions died. How similar is Big Food?

While the tobacco industry ranks among the most substantial and successful of economic enterprises, tobacco consumption is associated with more deaths than any other product. Economic analysis of the markets for tobacco products, particularly cigarettes, has contributed considerable insight to debates about the importance of the industry and the appropriate roles of public policy in grappling with the health consequences of tobacco. Certainly the most significant example of this phenomenon has been the rapidly expanding and increasingly sophisticated body of research on the effects of price increases on cigarette consumption. Because excise tax comprises an important component of price, the resultant literature has played a prominent role in legislative debates about using taxation as a principal tool to discourage smoking. In addition to informing legislative debates, this literature has contributed both theory and empirical evidence to the growing interest in modeling the demand for addictive products.This chapter examines this body of research in detail, as well as a variety of equity and efficiency concerns accompanying debates about cigarette taxation. Coverage also includes economic analysis of the role of other tobacco control policies, such as restrictions on advertising, of special interest due to their prominence in debates about tobacco control. The chapter concludes with consideration of research addressing the validity of the tobacco industry's argument that its contributions to employment, tax revenues, and trade balances are vital to the economic health of states and nations. This argument is one of the industry's principal weapons in its battle against policy measures intended to reduce tobacco product consumption.

OBJECTIVE To provide a comprehensive review of interventions and policies aimed at reducing youth cigarette smoking in the United States, including strategies that have undergone evaluation and emerging innovations that have not yet been assessed for efficacy. DATA SOURCES Medline literature searches, books, reports, electronic list servers, and interviews with tobacco control advocates. DATA SYNTHESIS Interventions and policy approaches that have been assessed or evaluated were categorised using a typology with seven categories (school based, community interventions, mass media/public education, advertising restrictions, youth access restrictions, tobacco excise taxes, and direct restrictions on smoking). Novel and largely untested interventions were described using nine categories. CONCLUSIONS Youth smoking prevention and control efforts have had mixed results. However, this review suggests a number of prevention strategies that are promising, especially if conducted in a coordinated way to take advantage of potential synergies across interventions. Several types of strategies warrant additional attention and evaluation, including aggressive media campaigns, teen smoking cessation programmes, social environment changes, community interventions, and increasing cigarette prices. A significant proportion of the resources obtained from the recent settlement between 46 US states and the tobacco industry should be devoted to expanding, improving and evaluating “youth centred” tobacco prevention and control activities.

https://tobaccocontrol.bmj.com/content/tobaccocontrol/9/1/47.full.pdf

Kenneth E. Warner

Papers

Preventing Mental, Emotional, and Behavioral Disorders Among Young People: Progress and Possibilities

The economics of smoking

The perils of ignoring history: Big Tobacco played dirty and millions died. How similar is Big Food?

The economics of smoking

Investing in youth tobacco control: a review of smoking prevention and control strategies